mbiomics’s €30M Series A marks a key transition point for the microbiome space—from promising biology to clinical and manufacturing execution.
The company is building Live Biotherapeutic Products (LBPs)—oral therapies made from defined combinations of live bacteria—designed to restore microbiome function in a controlled, pharmaceutical-grade format. This directly addresses one of the field’s biggest bottlenecks: while approaches like fecal microbiota transplantation (FMT) have shown efficacy, they remain variable, non-standardized, and difficult to scale.What differentiates mbiomics is its full-stack platform approach—combining AI-driven design of microbial consortia, proprietary analytics, co-cultivation, and manufacturing capabilities. This allows them to move beyond trial-and-error biology toward engineered, reproducible microbiome drugs.